Related Experiment Video
Updated: May 9, 2026

RhoC GTPase Activation Assay
Published on: August 22, 2010
RhoGDIα downregulates androgen receptor signaling in prostate cancer cells
Yezi Zhu1, Chengfei Liu, Ramakumar Tummala
1Department of Urology and Cancer Center, University of California at Davis, Sacramento, California; Graduate Program of Pharmacology and Toxicology, University of California at Davis, Sacramento, California.
Introduction:
Treatment of primary prostate cancer (CaP) is the withdrawal of androgens. However, CaP eventually progresses to grow in a castration-resistant state due to aberrant activation of androgen receptor (AR). Understanding the mechanisms leading to the aberrant activation of AR is critical to develop effective therapy. We have previously identified Rho GDP Dissociation Inhibitor alpha (GDIα) as a novel suppressor in prostate cancer. In this study, we examine the effect of GDIα on AR signaling in prostate cancer cells.
Methods:
GDIα was transiently or stably transfected into several prostate cancer cell lines including LNCaP, C4-2, CWR22Rv1, and DU145. The regulation of AR expression by GDIα was analyzed by qRT-PCR and Western blot. AR activity was measured by luciferase reporter assays and electrophoretic mobility shift analysis (EMSA). Immunofluorescence assay was performed to study AR nuclear translocation. The interaction between GDIα and AR was examined by co-immunoprecipitation assays.
Results:
In this study, we have identified GDIα as a negative regulator of AR signaling pathway. Overexpression of GDIα downregulates AR expression at both mRNA and protein levels. Overexpression of GDIα is able to prevent AR nuclear translocation and inhibit transactivation of AR target genes. Co-immunoprecipitation assays showed that GDIα physically interacts with the N-terminal domain of AR.
Conclusions:
GDIα suppresses AR signaling through inhibition of AR expression, nuclear translocation, and recruitment to androgen-responsive genes. GDIα regulatory pathway may play a critical role in regulating AR signaling and prostate cancer growth and progression.
Insights
Rho GDP Dissociation Inhibitor alpha (GDIα) suppresses prostate cancer growth by inhibiting androgen receptor (AR) signaling. GDIα reduces AR expression and its nuclear translocation, offering a potential therapeutic target for castration-resistant prostate cancer.
Area of Science:
- Oncology
- Molecular Biology
- Cell Signaling
Background:
- Prostate cancer (CaP) progression to castration-resistant states involves aberrant androgen receptor (AR) activation.
- Understanding AR aberrant activation mechanisms is crucial for developing effective CaP therapies.
- Rho GDP Dissociation Inhibitor alpha (GDIα) was previously identified as a novel suppressor in prostate cancer.
Purpose of the Study:
- To investigate the effect of GDIα on AR signaling in prostate cancer cells.
- To elucidate the role of GDIα in regulating AR expression and activity.
- To explore the potential of GDIα as a therapeutic target for prostate cancer.
Main Methods:
- GDIα was transfected into prostate cancer cell lines (LNCaP, C4-2, CWR22Rv1, DU145).
- AR expression and activity were analyzed using qRT-PCR, Western blot, luciferase reporter assays, and EMSA.
- AR nuclear translocation and GDIα-AR interaction were assessed via immunofluorescence and co-immunoprecipitation assays.
Main Results:
- GDIα acts as a negative regulator of the AR signaling pathway.
- Overexpression of GDIα downregulates AR expression at both mRNA and protein levels.
- GDIα inhibits AR nuclear translocation and transactivation of AR target genes, interacting physically with the AR N-terminal domain.
Conclusions:
- GDIα suppresses AR signaling by inhibiting AR expression, nuclear translocation, and recruitment to androgen-responsive genes.
- The GDIα regulatory pathway is critical in modulating AR signaling, prostate cancer growth, and progression.
- GDIα represents a potential therapeutic target for managing castration-resistant prostate cancer.
Related Concept Videos
Receptor Downregulation in MVBs
The EGFR can initiate signaling pathways that lead to cell proliferation, migration, and differentiation. Overexpression of EGFR stimulates cells to proliferate. Excessive EGFR activation may...
Hedgehog Signaling Pathway
Hedgehog Signaling Pathway
GPCR Desensitization
Small GTPases - Ras and Rho
Three regulatory proteins control their activity:
Experimental RNAi

